Clinical trial
Open-label, Phase I/II Study to Evaluate Safety and Efficacy of Asciminib With Chemotherapy Followed by Asciminib Plus Blinatumomab in Pediatric, Adolescent, and Young Adults With Relapsed or Refractory BCR::ABL1-positive (Philadelphia Positive, Ph+) or BCR::ABL1-like (Ph-like) ALL
NCT07387926 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-label, Phase I/II Study to Evaluate Safety and Efficacy of Asciminib With Chemotherapy Followed by Asciminib Plus Blinatumomab in Pediatric, Adolescent, and Young Adults With Relapsed or Refractory BCR::ABL1-positive (Philadelphia Positive, Ph+) or BCR::ABL1-like (Ph-like) ALL
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- July 5, 2026
- Completion date
- May 30, 2036
- Enrollment
- 50 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, leukemia, lymphoblastic, acute, philadelphia-positive, philadelphia chromosome positive acute lymphoblastic leukemia